Drug repositioning

Abstract

Rapid advances in pharmacotherapy and bioinformatics has led to the discovery and growing popularity of drug repositioning which includes re-investigating or recycling of existing drugs for new indications. There are innumerable advantages as well as challenges of drug repositioning. Since de-novo drug discovery takes plenty of time, effort and money, it has proved to a preferred alternative strategy for accelerated drug discovery. Moreover it is relatively inexpensive and carries minimal risk due to availability of previous pharmacological, safety and toxicology data. The strategies used are Known drug – new target/Drug focus/Drug-centric, Known target- new indication/Target focus/Target-centric and Disease focus/Disease-centric. Drug repositioning is a new breakthrough strategy to benefit patients by offering safer and effective treatment using shelved drugs.

Keywords

Drug repositioning - De-novo drug discovery - Pharmacotherapy

• References

• 1 Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3 2004; 673-683
• 2 Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 10 (07) 2014; 654-663
• 3 Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 20 (08) 2015; 1027-1034
• 4 Landers P. Drug industry's big push into technology falls short. Wall Street J February 2004; A1
• 5 Usdin S. Industry development: pipeline or flatline?. BioCentury. 1. 2002
• 6 Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med 24 2010; 1519
• 7 Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg 8 2011; 1317
• 8 Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals 6 2013; 1304-1321
• 9 Persidis A. The benefits of drug repositioning. Drug Discov World Spring 2011; 9-12
• 10 Cutting Edge Information. Pharmaceutical Product Relaunch: Preserving Market Share through Line Extension and New Market Entry Strategies. 2007 April http://www.prnewswire.com/news-releases/drug-repurposing-the-most-affordable-relaunch-option-for-pharma-companies-58268372.html
• 11 Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 57 2011; 153-160
• 12 Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 3 2004; 711-715
• 13 Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 9 (07) 2010; 519-522
• 14 Jin G, Wong S. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19 (05) 2014; 637-644
• 15 Gupta S, Sung B, Prasad S, Webb L, Aggarwal B. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34 (09) 2013; 508-517
• 16 Li YY, Jones SJ. Drug repositioning for personalized medicine. Genome Med 4 (03) 2012; 27
• 17 Naylor S, Schonfeld JM. Therapeutic drug repurposing, repositioning and rescue. Part I. Overview. Drug Discov World Winter Ed 2015; 54-62
• 18 Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?. Curr Treat Options Oncol 12 2011; 96-106
• 19 Blumenthal GM, Cortazar P, Zhang JJ. et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 17 (08) 2012; 1108-1113
• 20 Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 10 (06) 2009; 1069-1081
• 21 Caveney E, Caveney BJ, Somaratne R, Turner JR, Gourgiotis L. Pharmaceutical interventions for obesity: a public health perspective. Diabetes Obes Metab 13 (06) 2011; 490-497
• 22 Banach M, Piskorska B, Borowicz-Reutt KK. Propafenone enhances the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model. Pharmacol Rep 68 June (3) 2016; 555-560
• 23 von Philipsborn G, Gries J, Hofmann HP. et al. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung 34 1984; 1489-1497
• 24 Mori K, Ito H, Toda Y. et al. Successful management of intractable epilepsy with lidocaine tapes and continuous subcutaneous lidocaine infusion. Epilepsia 45 2004; 1287-1290
• 25 Enoki H, Hata H, Ohmori I, Maniwa S, Ohta H, Kobayashi K. Clinical applications and the effect of mexiletine on refractory epilepsies (Japanese). No To Hattatsu 32 2000; 29-34
• 26 Miyamoto A, Takahashi S, Oki J. A successful treatment with intravenous lidocaine followed by oral mexiletine in a patient with Lennox–Gastaut syndrome (Japanese). No To Hattatsu 31 1999; 459-464
• 27 Nakazawa M, Okumura A, Niijima S. et al. Oral mexiletine for lidocaine-responsive neonatal epilepsy. Brain Dev 35 2013; 667-669
• 28 Alexander GJ, Kopeloff LM, Alexander RB, Chatterjie N. Mexiletine: biphasic action on convulsive seizures in rodents. Neurobehav Toxicol Teratol 8 1986; 231-235
• 29 de Oliveira GG, Borges MA. Propranolol action in chronically unstable generalized epilepsy. Am J Ther 1 1994; 38-41
• 30 Borowicz KK, Banach M. Antiarrhythmic drugs and epilepsy. Pharmacol Rep 66 2014; 545-551
• 31 Lathers CM, Stauffer AZ, Tumer N, Kraras CM, Goldman BD. Anticonvulsant and antiarrhythmic actions of the beta blocking agent timolol. Epilepsy Res 4 1989; 42-54
• 32 Ozbakis-Dengiz G, Bakirci A. Anticonvulsant and hypnotic effects of amiodarone. J Zhejiang Univ Sci B 10 2009; 317-322
• 33 Vezzani A, Wu HQ, Stasi MA, Angelico P, Samanin R. Effect of various calcium channel blockers on three different models of limbic seizures in rats. Neuropharmacology 27 1988; 451-458
• 34 Wurpel JN, Iyer SN. Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia 35 1994; 443-449
• 35 Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46 2005; 967-969
• 36 Schmitt FC, Dehnicke C, Merschhemke M, Meencke HJ. Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy Behav 17 2010; 565-568
• 37 Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38 2004; 1631-1634